Breaking News

Tweet TWEET

All Physicians in Switzerland Are Now Able to Prescribe Sucampo's AMITIZA(R) for Chronic Idiopathic Constipation

All Physicians in Switzerland Are Now Able to Prescribe Sucampo's AMITIZA(R)
for Chronic Idiopathic Constipation

Swiss Bundesamt fur Gesundheit (BAG) Lifts Several Key Restrictions to AMITIZA
Specialty List, Increasing Patient Access

BETHESDA, Md., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Sucampo AG ("SAG"), a wholly
owned subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"),
headquartered in Zug, Switzerland, announced today that all physicians in
Switzerland are now able to prescribe AMITIZA^® (lubiprostone) for chronic
idiopathic constipation (CIC), as a result of the revision of the
reimbursement limitations by the Bundesamt für Gesundheit (BAG), effective
February 1, 2014.

In September 2013, SAG requested that the BAG revise several limitations with
which AMITIZA was first approved for reimbursement and inclusion in the
specialty list (SL), to make it easier to prescribe AMITIZA to patients who
have failed previous treatments with at least two laxatives over a nine month
period. The SL limitations that were revised are:

  *All Swiss physicians, not just gastroenterologists, are now allowed to
    prescribe AMITIZA;
  *The change in the maximum treatment duration of AMITIZA increased from 12
    to 52 weeks before a review is needed by a health insurance health care
    practitioner; and
  *The BAG removed from AMITIZA's SL a group limitation pertaining to the
    number of AMITIZA packs that physicians can prescribe at one time.

CIC has been estimated to occur in about 1 million people in Switzerland.^1 A
study was conducted in ten European countries, including Switzerland, and 28%
of the participants suffering from constipation for at least 6 months were
dissatisfied with their current treatment options using
laxatives.^2Safety-related and adverse-effect concerns were also among the
reasons reported for dissatisfaction in this study.^2 As a result, 83% of
these patients are interested in seeking alternative methods to relieve their
constipation.^2 Additionally, patients in this study reported they want
relief from all of their symptoms and to feel normal.

AMITIZA is the world's first chloride channel activator that increases
intestinal fluid secretion and softens stool, which facilitates the passage of
stool and alleviates symptoms associated with CIC.^3AMITIZA has been
prescribed globally 8 million times since 2006.

"Chronic idiopathic constipation is very common and difficult to treat, with
many patients dissatisfied with their current treatment.Constipation greatly
affects the quality of life of those who suffer from it, and it is in their
best interests to quickly obtain effective therapy," said Dr. Helene D.
Schaufelberger Uhr, specialized physician in gastroenterology (FMH) in Lugano,
Switzerland."Expanding the prescribing physicians to include all physicians
makes it possible for these physicians to prescribe a drug that has been
demonstrated to be effective and to normalize bowel function without having to
wait for a specialist consultation."

"We are pleased with today's announcement that we believe will expand access
to AMITIZA in Switzerland," said Ryuji Ueno, M.D., Ph.D., Ph.D., Chairman,
Chief Executive Officer and Chief Scientific Officer of Sucampo."Allowing all
physicians to prescribe AMITIZA and increasing the duration of treatment are
positive steps to increasing the availability of the product to patients in
Switzerland."

About AMITIZA

In the United States, AMITIZA capsules are indicated for the treatment of
chronic idiopathic constipation (CIC) in adults and OIC in adults with
chronic, non-cancer pain (24 mcg twice daily). The effectiveness in patients
with OIC taking diphenylheptane opioids (e.g., methadone) has not been
established. AMITIZA is also indicated for irritable bowel syndrome with
constipation (IBS-C) in women > 18 years old (8 mcg twice daily).

Important Safety Information

  *AMITIZA (lubiprostone) is contraindicated in patients with known or
    suspected mechanical gastrointestinal obstruction. Patients with symptoms
    suggestive of mechanical gastrointestinal obstruction should be thoroughly
    evaluated by the treating healthcare provider (HCP) to confirm the absence
    of such an obstruction prior to initiating AMITIZA treatment.
  *Patients taking AMITIZA may experience nausea. If this occurs, concomitant
    administration of food with AMITIZA may reduce symptoms of nausea.
    Patients who experience severe nausea should inform their HCP.
  *AMITIZA should not be prescribed to patients that have severe diarrhea.
    Patients should be aware of the possible occurrence of diarrhea during
    treatment. Patients should be instructed to discontinue AMITIZA and inform
    their HCP if severe diarrhea occurs.
  *Patients taking AMITIZA may experience dyspnea within an hour of first
    dose. This symptom generally resolves within three hours, but may recur
    with repeat dosing. Patients who experience dyspnea should inform their
    HCP. Some patients have discontinued therapy because of dyspnea.
  *In clinical trials of AMITIZA (24 mcg twice daily vs placebo; N=1113 vs
    N=316, respectively) in patients with CIC, the most common adverse
    reactions (incidence > 4%) were nausea (29% vs 3%), diarrhea (12% vs <
    1%), headache (11% vs 5%), abdominal pain (8% vs 3%), abdominal distension
    (6% vs 2%), and flatulence (6% vs 2%).
  *In clinical trials of AMITIZA (24 mcg twice daily vs. placebo; N=860 vs.
    N=632) in patients with OIC, the most common adverse reactions (incidence
    > 4%) were nausea (11% vs 5%) and diarrhea (8% vs 2%).
  *In clinical trials of AMITIZA (8 mcg twice daily vs. placebo; N=1011 vs.
    N=435, respectively) in patients with IBS-C the most common adverse
    reactions (incidence > 4%) were nausea (8% vs 4%), diarrhea (7% vs 4%),
    and abdominal pain (5% vs 5%).
  *Concomitant use of diphenylheptane opioids (e.g., methadone) may interfere
    with the efficacy of AMITIZA.
  *The safety of AMITIZA in pregnancy has not been evaluated in humans. Based
    on animal data, AMITIZA may cause fetal harm. AMITIZA should be used
    during pregnancy only if the potential benefit justifies the potential
    risk to the fetus. Caution should be exercised when AMITIZA is
    administered to a nursing woman. Advise nursing women to monitor infants
    for diarrhea.
  *Reduce the dosage in CIC and OIC patients with moderate and severe hepatic
    impairment. Reduce the dosage in IBS-C patients with severe hepatic
    impairment.

Please visit www.sucampo.com/productsfor complete Prescribing Information and
for further information.

About Sucampo Pharmaceuticals, Inc. and Sucampo AG

Sucampo AG, based in Zug, Switzerland, is a wholly-owned subsidiary of Sucampo
Pharmaceuticals, Inc., a global biopharmaceutical company focused on the
discovery, development and commercialization of drugs based on ion channel
activators knows as prostones. Discovered by the company's scientific founder,
prostones are naturally occurring fatty acid metabolites with unique
physiological activities. Sucampo has two marketed products – AMITIZA and
RESCULA^® – and a pipeline of prostone-based product candidates in clinical
development. A global company, Sucampo is headquartered in Bethesda, Maryland,
and has operations in the United Kingdom, Switzerland and Japan. For more
information, please visit www.sucampo.com.

The Sucampo logo and the tagline, The Science of Innovation, are registered
trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.
RESCULA is a registered trademark of R-Tech Ueno, Ltd, and has been licensed
to Sucampo AG.

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of
pharmaceutical industry regulation and health care legislation; Sucampo's
ability to accurately predict future market conditions; dependence on the
effectiveness of Sucampo's patents and other protections for innovative
products; the risk of new and changing regulation and health policies in the
U.S. and internationally and the exposure to litigation and/or regulatory
actions. No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Sucampo undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new
information, future events, or otherwise. Forward-looking statements in this
presentation should be evaluated together with the many uncertainties that
affect Sucampo's business, particularly those mentioned in the risk factors
and cautionary statements in Sucampo's most recent Form 8-K and 10-K, which
Sucampo incorporates by reference.

Sources

1.Suares et al. Prevalence of, and risk factors for, chronic idiopathic
    constipation in the community: systematic review and meta-analysis. Am J
    Gastroenterol. 2011; 106:1582-1591.
2.S. Müller-Lissner, J. Tack, Y. Feng, F. Schenck & R. Specht Gryp. Levels
    of satisfaction with current chronic constipation treatment options in
    Europe – an internet survey. Aliment Pharmacol Ther 2013; 37: 137–145.
3.AMITIZA Prescribing Information, 2013.

Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo
Pharmaceuticals).

Twitter LinkedIn

CONTACT: Silvia Taylor
         Senior Vice President, IR, PR, and Corporate Communications
         1-240-223-3718
         staylor@sucampo.com

Sucampo Logo
 
Press spacebar to pause and continue. Press esc to stop.